[HTML][HTML] CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis

…, E Gane, J Taubel, J Kao, M Fontana… - … England Journal of …, 2021 - Mass Medical Soc
Background Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening
disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in …

Nonbiopsy diagnosis of cardiac transthyretin amyloidosis

…, AWJM Glaudemans, T Rezk, M Fontana… - Circulation, 2016 - Am Heart Assoc
Background— Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

…, T Damy, U Eriksson, M Fontana… - European heart …, 2021 - academic.oup.com
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

…, DK Butler, AD Otter, K Menacho, M Fontana… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided
with the spread of variants of concern. We investigated whether single-dose vaccination, …

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

…, T Cutino-Moguel, M Andiapen, M Fontana… - Science …, 2020 - science.org
Understanding the nature of immunity following mild/asymptomatic infection with SARS-CoV-2
is crucial to controlling the pandemic. We analyzed T cell and neutralizing antibody …

Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis

M Fontana, S Pica, P Reant, A Abdel-Gadir, TA Treibel… - Circulation, 2015 - Am Heart Assoc
Background— The prognosis and treatment of the 2 main types of cardiac amyloidosis,
immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially …

Native T1 mapping in transthyretin amyloidosis

M Fontana, SM Banypersad, TA Treibel… - JACC: Cardiovascular …, 2014 - jacc.org
Objectives : The aims of the study were to explore the ability of native myocardial T1
mapping by cardiac magnetic resonance to: 1) detect cardiac involvement in patients with …

Immune boosting by B. 1.1. 529 (Omicron) depends on previous SARS-CoV-2 exposure

…, MO Diniz, A Ellis, K Feehan, M Finlay, M Fontana… - Science, 2022 - science.org
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …

Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study

M Fontana, SM Banypersad, TA Treibel, A Abdel-Gadir… - Radiology, 2015 - pubs.rsna.org
Purpose To investigate cardiac magnetic resonance (MR) imaging measurements of
extracellular volume (ECV) and total cell volume in immunoglobulin light-chain amyloidosis (AL) …

Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression

M Fontana, A Martinez-Naharro, L Chacko… - Cardiovascular …, 2021 - jacc.org
Objectives The purpose of this study was to determine the effect of patisiran on the cardiac
amyloid load as measured by cardiac magnetic resonance and extracellular volume (ECV) …